Brilliant!

LuPIN data released today proved that Veyonda is an exceptional drug.

The secret behind Veyonda is its method of composition, in which Idronoxil is DISSOLVED in a special suppository base.  This leads to its slow release after insertion, whereas a conventional suppository formulation would be expelled before it had time to work.  Slow release means that Idronoxil is present in the body in an active form for about 12 hours, so twice-daily administration leads to a 24-hour anti-cancer effect.

We now know, from presentations at the ASCO GU conference, that:

• Median survival for the first 36 patients in the LuPIN trial was 17.1 months
• Endocyte, which is testing LuPSMA as a monotherapy, expects to achieve OS of 13.7 months in its pivotal trial
• The Endocyte patients are not as sick as the LuPIN patients

This is a massive endorsement of the Noxopharm program.  Veyonda has delivered results that are much better than any alternative treatment can achieve.